U.S. Markets close in 3 hrs 52 mins

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
55.52-0.99 (-1.75%)
As of 12:07PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close56.51
Bid55.44 x 1200
Ask55.48 x 1200
Day's Range55.40 - 56.75
52 Week Range39.32 - 73.09
Avg. Volume792,779
Market Cap7.756B
Beta (5Y Monthly)1.60
PE Ratio (TTM)60.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates

    Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Misses Revenue Estimates

    Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 17.86% and -3.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Ionis Pharmaceuticals: Q2 Earnings Insights

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q2 results.Quarterly Results Earnings per share fell 2200.00% year over year to ($0.23), which beat the estimate of ($0.27).Revenue of $146,000,000 declined by 10.98% year over year, which missed the estimate of $148,870,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Ionis Pharmaceuticals hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 05, 2020View more earnings on IONSTime: 11:30 AMET Webcast URL: https://www.webcaster4.com/Webcast/Page/952/35523Technicals Company's 52-week high was at $73.09Company's 52-week low was at $39.32Price action over last quarter: Up 11.23%Company Overview Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline treats a wide variety of diseases, with an emphasis on cardiovascular, metabolic, severe, and rare diseases. Ionis sold rights to its first product, Kynamro, to Kastle Therapeutics after lackluster commercial success, but with partner Biogen brought its second drug, Spinraza for spinal muscular atrophy, to market. ATTR amyloidosis drug Tegsedi (inotersen) was approved in 2018 and cardiology drug Waylivra was approved in Europe in 2019.See more from Benzinga * Discovery: Q2 Earnings Insights * Recap: Horizon Therapeutics Q2 Earnings * Recap: Teva Pharmaceutical Q2 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.